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1. Introduction 
Macrodomain proteins contain at least one copy of an α/β 
globular domain of about 25 kDa that is evolutionarily conserved 
among eukaryotes, prokaryotes and viruses.1   Most of 
macrodomain proteins studied to date have been shown to 
function as ADP-ribose-binding modules.2 Humans have eleven 
macrodomain proteins according to the Pfam 26.0 database: 
macrodomain-containing proteins 1-3 (MDO1-3), five members 
of the poly(ADP-ribose) polymerase superfamily, and three H2A 
histone family members.3 
The function(s) of human MDO1 (as well as its homologs 
MDO2 and MDO3) are poorly known. MDO1 is localized in the 
mitochondria, suggesting a contribution on ATP generation, 
signaling, cellular differentiation and cellular growth.4 MDO1 
has been shown to function as a mono-ADP-ribosylhydrolase and 
a deacetylase of O-acetyl- ADP-ribose.5, 6 Indirectly, MDO1 may 
thus be implicated in gene silencing.7 Human MDO1 is 
associated with multiple cancers, such as ovarian carcinoma,8 
breast carcinoma,9 acute leukemia10 and prostate cancer.11 This 
makes the human MDO1 protein a promising new target for 
potential therapeutic applications.12 As only a few synthetic 
ligands have been reported, the endogenous ligand ADP-ribose 
should serve as a starting point for ligand-based design.  
The crystal structure of human MDO1 has been solved in the 
apo state (PDB code: 2X47).6 MDO1 is closest to MDO2 (PDB 
code: 4IQY)7 with a sequence identity of 57% and a root mean 
square deviation of 1.61 Å over 220 Cα atoms. MDO1 and 
MOD2 share essentially the same binding site for ADP-ribose, 
with two conservative changes only, Val271MDO1 to Ile189MDO2; 
Phe272MDO1 to Tyr190MDO2. Modeling the bound mode of ADP-
ribose in the apo MDO1 nonetheless requires a change in the 
side-chain conformation of Phe306MDO1 to make it similar to 
Phe224MDO2. Affinities towards ADP-ribose are comparable for 
these proteins with a KD of 0.9 µM for MDO1 and a KD of 0.15 
µM for MDO2.4, 13  
The first objective of this study is to explore modifications to 
the phosphate-ribose part of ADP-ribose. Phosphate-containing 
compounds typically show poor bioavailability, are not 
physiologically stable, show low permeability, and their 
syntheses may be challenging.14, 15 The second objective is to 
explore the binding pocket for a location that is able to 
accommodate large and flat fluorescent groups such as fused 
tricyclic aromatic rings. Such compounds, exemplified by 
fluorescein, would be useful fluorescent probes in cell-based 
studies of MDO1. 
We report the design and synthesis of two series of adenosine 
derivatives targeting the ADP-ribose binding pocket of MDO1. 
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Implementing an isosteric replacement strategy, adenosine was 
coupled to unsymmetrically substituted squaryldiamides and 
various amide linkers. Squaryldiamides possess two sp2 oxygen 
atoms that carry a double partial negative charge through their 
delocalized electrons, and have been reported to act as good 
mimics of the phosphate moiety.16, 17 An amide group acts also as 
a promising phosphate replacement, as exemplified by structural 
isosteres found in the Protein Data Bank.18 Amides have also 
been shown to be successful mimics of phosphodiester 
internucleoside linkages in RNA19 and they are synthetically 
feasible.  
 
2. Results 
2.1. Ligand-based design 
In the first series of derivatives, we designed eight 
asymmetrically substituted squaryldiamides with different 
lengths, shapes and polarities (Table 1). We chose four benzylic 
(compounds 21, 24, 26 and 28), aliphatic (compound 23), aryl 
(compounds 22 and 25), and heteroaromatic (compound 27) 
substituents. In the second series of five derivatives, adenosine 
analogs with an amide linker were designed (compounds 31, 33-
34, 38 and 39, Table 2). To investigate the replacement of the 
distal phosphate of ADP-ribose with a hydroxy or carboxyl 
group, three of these compounds were designed as derivatives of 
L-serine (compounds 31 and 34) and L-aspartic acid (compound 
33). The carboxyl group of aspartic acid is similar to the 
phosphate group especially in terms of geometry and pKa (pKa of 
3-5 for carboxylic acid vs. 1.54 and 6.31 for the pKa1 and pKa2 of 
phosphate).20 Compounds 31 and 33 are Fmoc-protected ones 
tested to explore the ability of the binding pocket to 
accommodate large and flat fluorescent groups. This could be 
employed in the development of fused tricyclic fluorescent 
probes for future screening studies of MDO1. Two compounds 
contained a tetrazolyl group (compounds 38 and 39) and were 
designed since tetrazole is a classical phosphate bioisosteric 
replacement21 with a pKa around 4.90.22 The compound 39 with 
the 1H proton of the tetrazole moiety substituted by a phenyl 
group was designed to study the effect of an acidic proton of the 
1H-tetrazole moiety for an enzymatic activity. 
 
2.2. Synthesis 
The compounds of the first series, the squaryldiamides 21-28, 
were synthesized in three reaction steps starting from diethyl 
squarate (4) and two different amines (Scheme 1). First, the key 
building block, acetonide-protected 5’-amino-5’-deoxyadenosine 
(3) was synthesized. We treated 2',3'-O-isopropylideneadenosine 
(1) first with diphenylphosphoryl azide (DPPA) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), and subsequently with 
sodium azide and 1,4,7,10,13-pentaoxacyclopentadecane (15-
crown-5) in 1,4-dioxane under reflux to yield the acetonide-
protected 5'-azido-5'-deoxyadenosine (2) in 86% yield. Next, the 
azido intermediate (2) was converted to the desired key building 
block (3) by using a modified Staudinger reaction in the presence 
of polymer-bound triphenylphosphine.20 The acetonide-protected 
5'-amino-5'-deoxyadenosine (3) was obtained in 70% yield. 
We started the synthesis of target compounds by treating 
diethyl squarate (4) with various aliphatic, aromatic and benzylic 
amines in ethanol to give eight differently substituted alkoxy 
amino squarates (5-12) in 25-92% yields. Only mono-substituted 
products were formed in this reaction, which was consistent with 
the literature.23 In a similar fashion, the acetonide-protected 5´-
amino-5´-deoxyadenosine (3) was reacted with alkoxy amino 
squarates 5-12. This transformation produced the acetonide-
protected and unsymmetrically 3,4-substituted cyclobut-3-ene-
1,2-diones 13-20 that were subsequently deprotected in the 
presence of aqueous trifluoroacetic acid (TFA) to give a set of 
eight different 3-(5’-amino-5’-deoxyadenosine)-4-
(alkylamino)cyclobut-3-ene-1,2-diones (21-28) in 45-90% yields. 
The synthesis of the amide series was started by coupling 
amine 3 with N-hydroxysuccinimide (OSu)-activated ester and 
Fmoc- and tert-butyl-protected amino acids (Fmoc-Ser(tBu)-OSu 
and Fmoc-Asp(OtBu)-OSu, respectively) to give compounds 29 
and 30 in 70 and 75% yields, respectively (Scheme 2). 
Deprotection of the acetonide- and the tert-butyl groups of 
compounds 29 and 30 was performed in the presence of TFA in 
H2O/CH2Cl2 to give the Fmoc-protected amino acid derivatives 
31 and 33 in 70 and 90% yields, respectively. The serine 
derivative 34 was obtained in 27% yield after deprotection of the 
Fmoc group with diethylamine (DEA) in N,N-
dimethylformamide (DMF). 
In the syntheses of the two tetrazole analogs 38 and 39, amine 
3 was first reacted with either 1H-tetrazole-5-acetic acid or [(1-
phenyl-1H-tetrazol-5-yl)thio]acetic acid using N,N,N′,N′-
tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) as a coupling reagent to give the 
amides 36 and 37 in 80 and 85% yields, respectively (Scheme 3). 
Subsequently, the acetonide-protecting groups of amides 36 and 
37 were removed with TFA/H2O/CH2Cl2 (5:1:4) to give the 
products 38 and 39 in 83 and 77% yields, respectively. 
 
2.3. Biological activities 
We first attempted to measure quantitatively the binding 
affinities of the set of compounds, together with those of 
benchmark nucleotides (ADP-ribose, ADP, AMP), using 
isothermal titration calorimetry. We also tried differential 
scanning fluorimetry, where the stabilizing effect of compounds 
on temperature-dependent denaturation is measured by the 
unspecific binding of a hydrophobic reporter dye to the protein 
core.
24
 Molecules that are better stabilizers are thought to be 
tighter binders. Unfortunately, as a result of these two 
experiments, no detection could be made in ITC and only very 
small ∆Tm could be obtained even for the ADP and AMP controls 
(less that one °C unit). For the endogenous substrate ADP-ribose 
to the human MDO1, the KD measured using isothermal titration 
calorimetry is in the order of 0.9 µM25 and the associated ∆Tm 
measured in this study was about 5 °C. Thus, the results suggest 
weaker affinities than for the endogenous substrate ADP-ribose, 
in the low to high µM if not mM. Overall, these findings are not 
surprising: it is unlikely that an optimal fit of the phosphate 
replacement in the binding pocket, associated with an affinity as 
good as that of ADP-ribose, will be found on a first try for our 
compounds.  
We therefore resorted to use a biochemical assay, where 
presence of mono-biotin-ADP-ribosylated SRPK2 is followed 
qualitatively using a western blot (Figure 1). In this setup the 
negative control is the mono-biotin-ADP-ribosylated SRPK2 
alone, whereas the positive control is composed of SPRK2 and 
MDO1 without an inhibitor. Inhibited MDO1 cannot efficiently 
hydrolyze the modification from SRPK2 resulting in stronger 
signal than the positive control. The analysis revealed that 28 and 
31, and to a lesser extent 27, inhibit the catalytic activity of 
MDO1. Compound 28 is more efficient inhibitor than 31 based 
on the visual comparison of their relative intensities.  
However, we could not confirm the results obtained from 
western blot using the Alphascreen-based activity assay for 
mono-ADP-ribosyl hydrolyzing macrodomains.26 The assay 
utilizes the same principle as the western blot and measures 
hydrolysis of ADP-ribosyl group from SRPK2. Dose-response 
  
measurements did not show any significant inhibition for 
compounds 28 and 31 against MDO1 or MDO2 (Supplementary 
Material S1) even at the highest compound concentration 6.6 
mM. This indicates that the ADP-ribose analogs lacking the 
distal ribose only show low potencies against macrodomains 
similar to ADP and AMP. 
 
 
Scheme 1. Synthesis of the squaryldiamide derivatives.a 
 
a
 Reagents and conditions: i) DPPA, DBU, NaN3, 15-crown-5, 1,4-dioxane, rt to 110 °C, overnight, 86%; ii) triphenylphosphine (polymer-bound), THF, H2O, rt, 
4 h, 70%; iii) amine, EtOH, 0 °C to rt, 2 h, 25-92%; iv) DIPEA, EtOH, rt, 5 h to overnight, 37-94%; v) TFA/H2O (4:1), rt, 5 h, 45-90%. 
Scheme 2. Synthesis of the amino acid derivatives.a 
 
 
 
 
 
 
 
a
 Reagents and conditions: i) Fmoc-Ser(tBu)-OSu or Fmoc-Asp(OtBu)-OSu, MeOH, rt, 2 h, 70-75%; ii) TFA/H2O/CH2Cl2 (4-5:1:1-4), rt, 5-24 h, 70-90%; iii) 
DEA, DMF, rt, 5 h, 27%. 
Scheme 3. Synthesis of the tetrazole derivatives.a 
 
    
 
a
 Reagents and conditions: i) 1H-tetrazole-5-acetic acid or [(1-phenyl-1H-tetrazol-5-yl)thio]acetic acid, HBTU, DIPEA, DMF rt, 4 h, 80-85%; ii) 
TFA/H2O/CH2Cl2 (5:1:4), rt, 4-5 h, 77-83%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Western blot analysis of the inhibition efficiency for MDO1 in 
the hydrolysis of mono-biotin-ADP-ribosylation from SRPK2 (A) 
compounds 21-28 (B) compounds 31-34, and 38-39. Compounds 21, 26-28 
and 33-39 were tested at 1 mM concentrations, and compounds 22-25 and 31 
were tested at 0.8 mM concentrations. Compound 35 is not described in this 
manuscript.27 
  
 
 
Table 1. Inhibition of ADP-ribosyl hydrolysis and docking 
scores for the compounds of the squaryldiamide series prepared 
as shown Scheme 1.a 
 
 
 
 
Compound R 
Docking 
score 
Inhibition 
AMP - -10.376 - 
ADP - -11.029 - 
ADP-
ribose 
- -14.566 +++ 
21 
 
-10.203 - 
22 
 
-8.972 - 
23 
 
-10.017 - 
24 
 
-9.918 - 
25 
 
-10.171 - 
26 
 
-10.692 - 
27 
 
-10.082  + 
28 
 
-11.239 +++ 
a
 Readout: -, no reading; +, weak reading; +++, high reading. Compounds 
were tested at 0.8-1 mM concentrations. Docking scores were calculated 
using the XP scoring function (Schrödinger Ltd) The lower the value, the 
more favorably the compound is predicted to bind. 
 
2.4. Docking simulations of ADP-ribose, compound 28 and 
compound 31. 
As part of the design process, all the compounds were 
prospectively docked to the three-dimensional structure of 
MDO1. We hypothesized that the crystal structure of MDO2 can 
be used 
 
Table 2. Inhibition of ADP-ribosyl hydrolysis and docking 
scores for the compounds of the amino acid series (Schemes 2 
and 3).a 
 
 
 
 
Compound R 
Docking 
score 
Inhibition 
31 
 
-10.043 ++ 
33 
 
-11.902 - 
34 
 
-10.678 - 
38 
 
-9.973 - 
39 
 
-9.894 - 
a
 Readout: -, no reading; ++, moderate reading. Compounds were tested at 
0.8-1 mM concentrations. Docking scores were calculated using the XP 
scoring function (Schrödinger Ltd) The lower the value, the more favorably 
the compound is predicted to bind. 
to derive the binding mode of ADP-ribose to MDO1. This is 
especially supported by the near-identical binding sites. Since the 
binding site of the apo structure is occluded, the conformation of 
the side chains Val181 and Phe306 had to be modified to 
accommodate nucleotide ligands, and this was done by 
reconstructing a homology model of MDO1 based on MDO2 
(Supplementary Material S2). Redocking ADP-ribose to MDO1 
led to a very similar binding mode as in MDO2 (Figure 2A and 
Figure 2B) but only after a distance restraint had forced the 
adenine ring onto its binding site. The docking procedure 
validated nonetheless that in theory no large clashes occurred at 
the binding site and that hydrogen-bonding groups of the protein 
were geometrically suitably positioned, i.e. that the compounds 
were potentially inhibitors of MDO1. ADP-ribose obtained 
clearly the best score with a value of -14.566), while the docking 
scores of the second most active compounds (ADP and 28) were 
also among the best. We next focused on the analysis of the most 
active compounds, 28 and 31 (Figure 2C and 2D). 
For compounds 28 and 31, the adenine ring and the ribose 
were constrained to occupy a site equivalent to that predicted for 
ADP-ribose (Figure 2). The adenine ring is sandwiched between 
the planar phenyl group of Phe306 (pi-pi interaction) and the 
isopropyl side-chain of Val183. The amino group of adenine (N6) 
is donating a hydrogen bond to the Asp160 carboxyl group. In 
  
addition, the N1 nitrogen from the Watson-Crick edge of adenine 
accepts a hydrogen bond from the main-chain nitrogen of Ile161. 
The hydrogen of the ribose O3' hydroxy group donates a 
hydrogen bond to the side-chain of Thr269 in many complexes. 
We next examined which groups are docked in place of the 
phosphate groups of ADP-ribose. In MDO2, the negative charge  
Figure 2. The complex of human MDO2 with (A) ADP-ribose (PDB file: 4IQY) and predicted binding modes of modeled human MDO1 in complex with 
(B) ADP-ribose, (C) compound 28, and (D) compound 31. Carbon, oxygen, and nitrogen atoms are shown in black, red, and blue, respectively. The carbon 
atoms of binding site residues are shown in green. Putative hydrogen bonds are depicted as dashed lines in yellow. 
 
of the proximal phosphate is neutralized by the positively 
charged macrodipole at the N-terminus of helix 8. This 
macrodipole is generated by the sum of the dipolar contributions 
from the helical backbone. In addition, on the top of this helix, 
the main chain NH of Val101 in MDO2 donates a hydrogen bond 
to an oxygen atom of the proximal phosphate (Figure 2A); in 
MDO1 the NH of the equivalent Val183 interacts with this time 
the distal ADP-ribose phosphate, probably reflecting docking 
uncertainties (Figure 2B). For neither 28 nor 31 the amide 
nitrogen bonds with Gly182 and Val183 is satisfied in the docked 
poses. This may reflect docking uncertainties, or water molecules 
that do play important role in molecular recognition and may 
bridge these hydrogen-bonding groups, although they are not 
included in the docking simulation. On the other hand, it is 
possible that a next generation of compounds could be designed 
that contain a hydrogen-bond acceptor pointing towards the main 
chain NH groups of Val183 and Gly182. Instead, for both 28 and 
31 new interactions were created with Ser268 and Thr269. In 
particular, an oxygen atom of the linker was found at close 
distance of the Val171 main-chain nitrogen, indicating the 
possibility of a hydrogen bond. 
The third site of interest is that of the distal ribose. The ribose 
especially benefits from interaction with Asp160 in MDO1 and 
its equivalent Asp78 in MDO2. An equivalent interaction is not 
possible for 28 and 31 that are devoid of oxygen or nitrogen 
atoms in this region of the binding site. In contrast, an especially 
prominent interaction is stacking on Phe272. Explaining the 
selectivity of 28 over its analogs 21, 24, 26 and 27 is highly 
speculative, but it may be that the methyl groups at the para 
position create additional hydrophobic interactions. 
 
3. Conclusions 
In conclusion, we designed and synthesized novel ADP-ribose 
analogs targeted to MDO1 by replacing the phosphates with 
bioisosteres and a set of aromatic substituents in place of the 
distal ribose. As a result, two inhibiting compounds were found, 
providing early indication about the SAR of MDO1 compounds. 
The results suggested that both a squaryldiamide and an amide 
linker were accepted by the binding site. A 4-methyl substituent 
in the phenyl group of 28 provided additional potency perhaps 
through interaction with an aromatic phenylalanine in the binding 
site and could be used as a starting point for design of more 
potent compounds. The next generation of derivatives could also 
have an additional hydrogen-bond acceptor pointing towards the 
main chain NH of Val183 and Gly182 to gain activity. Based on 
compound 31 the ADP-ribose binding groove may accommodate 
a bulky fluorophore group which could be a way for generation 
of tool compounds for studies on biological roles of the 
macrodomains. As the distal ribose is a key feature of the ADP-
ribose, proper interactions need to be designed at this region of 
the binding pocket in order to achieve more potent inhibitors.  
 
  
4. Experimental 
4.1. Materials and general procedures 
All reagents were commercially available. They were acquired 
from Fluka (Buchs, Switzerland) and Sigma-Aldrich 
(Schnelldorf, Germany) and were used without further 
purification. All reactions in anhydrous solvents were conducted 
in oven-dried glassware under argon. Thin-layer chromatography 
(TLC) was performed using Silica Gel 60 F254 (Merck) and Silica 
Gel 60 NH2 F254s aluminum sheets (Merck), visualized by UV 
illumination and stained with ninhydrin in EtOH (1.5% w/v). 
Column chromatography was performed with an automated high 
performance flash chromatography Biotage Sp4-system or with a 
Isolera Spektra One-system (Uppsala, Sweden) using a 0.1-mm 
path length flow cell UV-detector/recorder module (fixed 
wavelength 254 nm) for the Sp4-system or a variable UV-VIS 
(200-800 nm) photodiode array detector for the Isolera Spektra 
One-system, and the indicated mobile phase. The 1H and 13C 
NMR spectra were recorded on a Varian Mercury-VX 300 
(Agilent Technologies, Santa Clara, California, USA) or Bruker 
Ascent 400 (Bruker Corporation, Billerica, Massachusetts, USA) 
spectrometer as solutions in CDCl3, DMSO-d6 and CD3OD. 
Chemical shifts (δ) are reported as parts per million (ppm) 
relative to the solvent peak (CDCl3 7.26 and 77.16 ppm, DMSO-
d6 2.50 and 39.52 ppm, CD3OD 3.31 and 49.00 ppm). 
Multiplicities of peaks are represented by s (singlet), d (doublet), 
t (triplet), q (quartet), quintet (qn), and m (multiplet). HPLC–MS 
analyses were performed to determine purity of all tested 
compounds. Purity of all tested compounds was > 95%. Mass 
spectra were measured on a Bruker Daltonics Esquire-HPLC 
spectrometer, with XTerra MS RP18 column (4.6 mm × 30 mm, 
2.5 µm). High resolution mass spectra (HRMS) were measured 
on a Waters Synapt G2 (Waters Corporation, Milford, 
Massachusetts, USA) and reported for the molecular ions 
[M+H]+. 
 
4.2. Synthesis procedures 
Procedures for the synthesis and analysis of the remaining 
compounds are available in the Supplementary Material. 
4.2.1.  2 ′ , 3 ′-O-Isopropyl idene-5 '-azido-5'-
deoxyadenosine (2)  
To a solution of 2 ,´3´-O-isopropylideneadenosine (1.00 g, 3.25 
mmol) in dry 1,4-dioxane (10 mL), DPPA (1.40 g, 1.48 mL, 6.5 
mmol) and DBU (1.34 g, 1.50 mL, 9.8 mmol) were added 
dropwise. The reaction mixture was stirred at rt for 47 h. Sodium 
azide (1.06 g, 16.3 mmol) and 15-crown-5 (0.527 g, 0.064 mL, 
0.326 mmol) were added to the reaction mixture. The resulting 
mixture was irradiated in a microwave reactor at 110 °C for 4 h 
(1 bar, 600 rpm) and cooled to rt. Filtration of the reaction 
mixture and evaporation of the filtrate gave a residue that was 
redissolved in CHCl3 (90 mL). The organic phase was washed 
with water (3 × 15 mL) and brine (3 × 15 mL). The organic phase 
was dried with anhydrous Na2SO4, filtrated and evaporated to 
give a brown oil. The crude product was purified by column 
chromatography on silica gel (EtOAc/EtOH/n-heptane 3:1:4) 
yielding the azide 2 as an amorphous yellow solid (0.928 g, 86% 
yield) with some 15-crown-5 as an impurity. The product was 
used in the next step without further purification. Rf = 0.33 
(CHCl3/ EtOH, 20:1). 1H NMR (300 MHz, CDCl3) δppm 8.32 (s, 
1H), 7.90 (s, 1H), 6.23 (br s, 2H), 6.10 (d, J = 2.2 Hz, 1H), 5.45 
(dd, J = 6.3, 2.2 Hz, 1H), 5.04 (dd, J = 6.3, 3.3 Hz, 1H), 4.41–
4.31 (m, 1H), 3.55 (dd, J = 5.7, 2.9 Hz, 2H), 1.60 (s, 3H), 1.37 (s, 
3H). 13C NMR (75.4 MHz, CDCl3) δppm 156.0, 153.3, 149.3, 
140.0, 120.4, 114.9, 90.8, 85.8, 84.2, 82.2, 52.5, 27.3, 25.5; 
HRMS-ESI m/z calcd for C13H17N8O3 333.1418 [M+H]+, found 
333.1424. 1H NMR spectral data is consistent with those 
previously reported.28  
 
4.2.2.  2 ′ , 3 ′-O-Isopropyl idene-5' -am ino-5 '-
deoxyadenosine (3) 
Polymer-bound triphenylphosphine (loading: 1.4 mmol/g, 4.29 g, 
6.02 mmol) was suspended in anhydrous THF (60 mL). The 
mixture was left to stand for 5 min, then a solution of the azide 2 
(1.00 g, 3.01 mmol) in anhydrous THF (2 mL) was added. The 
suspension was stirred at rt for 4 h. Water (0.540 mL, 30.1 mmol) 
was added to the reaction mixture and it was stirred at rt 
overnight. The resin was washed with THF, the combined 
solutions were dried with anhydrous Na2SO4, filtrated, and 
evaporated. The crude product was purified by column 
chromatography on silica gel (CHCl3/MeOH 10:1 → 4:1) to give 
the compound 3 as a white solid (645 mg, 2.11 mmol, 70% 
yield). Rf = 0.25 (CHCl3 /MeOH, 1:4). 1H NMR (300 MHz, 
CDCl3) δppm 8.34 (s, 1H), 7.91 (s, 1H), 6.03 (d, J = 3.1 Hz, 1H), 
5.68 (br s, 2H), 5.46 (dd, J = 6.5, 3.1 Hz, 1H), 5.04 (dd, J = 6.4, 
3.4 Hz, 1H), 4.27 (dd, J = 9.5, 4.3 Hz, 1H), 3.05 (dd, J = 13.4, 
4.6 Hz, 1H), 2.98 (dd, J = 13.4, 5.8 Hz, 1H), 1.91 (br s, 2H), 1.62 
(s, 3H), 1.39 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δppm 155.8, 
153.4, 150.3, 140.2, 120.7, 114.8, 91.0, 87.5, 83.9, 82.1, 44.0, 
27.5, 25.6; HRMS-ESI m/z calcd for C13H19N6O3 307.1513 
[M+H]+, found 307.1516. 
 
4.2.3.  3-Ethoxy-4- [(4-
f luorobenzyl )amino]cyclobut-3-ene-1,2-dione (8) 
4-Fluorobenzylamine (156 µL, 171 mg, 1.36 mmol) was added at 
0 °C to a solution of 3,4-diethoxycyclobut-3-ene-1,2-dione (0.20 
mL, 2300 mg, 1.36 mmol) in EtOH (10 mL). The reaction 
mixture was stirred at rt for 2 h. The solvents were removed in 
vacuo and the residue was purified by column chromatography 
on silica gel (n-heptane/EtOAc 1:1) to give compound 8 as a 
white solid (189 mg, 0.76 mmol, 56% yield). Rf = 0.46. 1H NMR 
(400 MHz, CDCl3) δppm 7.33-7.27 (m, 2H), 7.11–6.91 (m, 2H), 
5.72 (br s, 1H), 4.77 (br s, 3H), 4.57 (br s, 1H), 1.45 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δppm 189.5, 183.1, 177.9, 
172.3, 162.7 (d, J = 247.3 Hz), 132.9, 129.7, 116.07 (d, J = 21.6 
Hz), 70.1, 48.1, 16.0; HRMS-ESI m/z calcd C13H13FNO3 
250.0879 [M+H]+, found 250.0880. 
 
4.2.4.  3-Ethoxy-4- [(3-nit rophenyl )am ino]cyclobut-
3-ene-1,2-dione (9) 
3-Nitroaniline (85 mg, 0.68 mmol) was added at 0 °C to a 
solution of 3,4-diethoxycyclobut-3-ene-1,2-dione (0.10 mL, 120 
mg, 0.68 mmol) in EtOH (3 mL). The reaction mixture was 
stirred at rt for 5 h. The solvents were removed in vacuo and the 
residue was purified by column chromatography on silica gel (n-
hexane/EtOAc 1:1) to give compound 9 as an orange solid (126 
mg, 0.48 mmol, 71% yield). Rf = 0.29 (CHCl3/MeOH, 10:1). 1H 
NMR (300 MHz, DMSO-d6) δppm 11.06 (br s, 1H), 8.32 (t, J = 
2.2 Hz, 1H), 7.92 (ddd, J = 8.1, 2.2, 0.9 Hz, 1H), 7.78 (ddd, J = 
8.2, 2.3, 1.0 Hz, 1H), 7.64 (t, J = 8.2 Hz, 1H), 4.80 (q, J = 7.1 Hz, 
2H), 1.44 (t, J = 7.1 Hz, 3H); 13C NMR (75.4 MHz, DMSO-d6) 
δppm 187.4, 184.2, 178.9, 169.3, 148.3, 139.4, 130.5, 125.3, 118.0, 
113.6, 69.9, 15.5; HRMS-ESI m/z calcd C12H11N2O5 263.0662 
[M+H]+, found 263.0668. 
 
  
4.2.5.  3-Ethoxy-4- [(4-
m ethoxybenzyl)am ino]cyclobut -3-ene-1,2-d ione 
(10) 
4-Methoxybenzylamine (178 µL, 1.36 mmol) was added at 0 °C 
to a solution of 3,4-diethoxycyclobut-3-ene-1,2-dione (0.20 mL, 
240 mg, 1.36 mmol) in EtOH (5 mL). The reaction mixture was 
stirred at rt for 2 h. The solvents were removed in vacuo, and the 
residue was purified by column chromatography on silica gel (n-
hexane/EtOAc 1:1) to give compound 10 as a white solid (291 
mg, 1.17 mmol, 86% yield). Rf = 0.41 (n-hexane/EtOAc, 1:1). 1H 
NMR (300 MHz, CHCl3) δppm 7.24–7.02 (m, 3H), 6.91–6.81 (m, 
2H), 4.75 (br s, 2H), 4.52 (br s, 2H), 3.78 (s, 3H), 1.42 (t, J = 7.5 
Hz, 1H); HRMS-ESI m/z calcd for C14H16NO4 262.1001 [M+H]+, 
found 262.1079. 
 
4.2.6.  3- [4-Fluorobenzy l)am ino]-4- (2´, 3´ -O-
i sopropylidene-5´ -amino-5´-
deoxyadenosine)cyclobut-3-ene-1,2-dione (16) 
To a solution of compound 8 (179 mg, 0.72 mmol) in EtOH (10 
mL) was added DIPEA (0.74 mL, 0.79 mmol) and 3 (241 mg, 
0.79 mmol). The reaction mixture was stirred at rt for 6 h. The 
solvent was removed in vacuo, and the residue was purified by 
column chromatography on silica gel (CHCl3/MeOH 10:1) to 
give 16 as a white solid (306 mg, 0.6 mmol, 84% yield). Rf = 
0.73 (CHCl3/MeOH, 10:1). 1H NMR (400 MHz, DMSO-d6) δppm 
8.33 (s, 1H), 8.14 (s, 1H), 7.89 (br s, 1H), 7.34 (s, 4H), 7.17 (t, J 
= 8.6 Hz, 2H), 6.19 (d, J = 2.8 Hz, 1H), 5.43 (dd, J = 6.6, 2.8 Hz, 
1H), 5.03 (dd, J = 6.4, 3.4 Hz, 1H), 4.66 (d, J = 6.6 Hz, 2H), 
4.37–4.17 (m, 1H), 4.00–3.70 (m, 2H), 1.54 (s, 3H), 1.32 (s, 3H). 
13C NMR (101 MHz, DMSO-d6) δppm 182.7, 182.5, 167.9, 
167.6, 161.4 (d, J = 243 Hz), 156.1, 152.9, 148.8, 139.8, 
135.2, 129.6 (d, J = 8.4 Hz), 119.1, 115.4 (d, J = 21.2 Hz), 
113.7, 88.7, 85.0, 83.1, 81.2, 46.0, 45.1, 27.0, 25.3; HRMS-
ESI m/z calcd C24H25FN7O5 510.1901 [M+H]+, found 510.1901. 
 
4.2.7.  3- (2´,3´ -O-Isopropylidene-5´-am ino-5´-
deoxyadenosine)-4-[(3-
ni trophenyl)am ino]cyclobut -3-ene-1, 2-d ione (17) 
To a solution of compound 9 (64 mg, 0.31 mmol) in EtOH (3 
mL) was added DIPEA (0.060 mL, 0.33 mmol) and 3 (0.10 g, 
0.33 mmol). The reaction mixture was stirred at rt for 5 h. The 
solvent was removed in vacuo, and the residue was purified by 
column chromatography on silica gel (CHCl3/MeOH 10:1) to 
give compound 17 as a yellow solid (155 mg, 0.30 mmol, 90%). 
Rf = 0.46 (CHCl3/MeOH, 10:1). 1H NMR (300 MHz, DMSO-d6) 
δppm 9.95 (br s, 1H), 8.35 (s, 2H), 8.15 (s, 1H), 7.82 (ddd, J = 8.1, 
2.2, 0.9 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.58 (t, J = 8.1 Hz, 
1H), 7.30 (s, 2H), 6.24 (d, J = 2.6 Hz, 1H), 5.47 (dd, J = 6.3, 2.7 
Hz, 1H), 5.09 (dd, J = 6.3, 3.7 Hz, 1H), 4.33 (dt, J = 8.0, 4.2 Hz, 
1H), 4.04 (dd, J = 14.0, 4.8 Hz, 1H), 3.87 (dd, J = 13.9, 7.3 Hz, 
1H), 1.56 (s, 3H), 1.34 (s, 3H); 13C NMR (75.4 MHz, DMSO-d6) 
δppm 184.3, 180.5, 169.5, 163.0, 156.1, 152.8, 148.7, 148.6, 
140.3, 140.0, 130.6, 123.9, 119.2, 116.6, 113.8, 112.3, 88.6, 
84.9, 83.1, 81.0, 45.4, 27.0, 25.3; HRMS-ESI m/z calcd for 
C23H23N8O7 523.1684 [M+H]+, found 523.1689. 
 
4.2.8.  3- (2´,3´ -O-Isopropylidene-5´-am ino-5´-
deoxyadenosine)-4-[4-
m ethoxybenzyl)am ino]cyclobut -3-ene-1,2-d ione 
(18) 
To a solution of compound 10 (64 mg, 0.31 mmol) in EtOH (3 
mL) was added DIPEA (0.060 mL, 0.33 mmol) and 3 (0.10 g, 
0.33 mmol). The reaction mixture was stirred at rt for 5 h. The 
solvent was removed in vacuo, and the residue was purified by 
column chromatography on silica gel (CHCl3/MeOH 10:1) to 
give compound 18 as a white solid (150 mg, 0.30 mmol, 91% 
yield). Rf = 0.35 (CHCl3/MeOH, 10:1). 1H NMR (300 MHz, 
DMSO-d6) δppm 8.30 (s, 1H), 8.17 (s, 1H), 7.65 (br s, 1H), 7.31 
(br s, 2H), 7.22 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 6.19 
(d, J = 2.7 Hz, 1H), 5.42 (dd, J = 6.3, 2.6 Hz, 1H), 5.01 (dd, J = 
6.3, 3.5 Hz, 1H), 4.60 (d, J = 6.0 Hz, 2H), 4.30–4.20 (m, 1H), 
4.01–3.81 (m, 1H), 3.73 (s, 3H), 1.54 (s, 3H), 1.32 (s, 3H); 13C 
NMR (75.4 MHz, DMSO-d6) δppm 183.0, 182.6, 168.1, 167.8, 
159.0, 156.3, 153.2, 149.0, 140.3, 130.9, 129.2, 119.3, 114.3, 
89.0, 83.4, 81.4, 70.1, 55.4, 46.6, 45.4, 27.3, 25.5; HRMS-ESI 
m/z calcd C25H28N7O6 522.2096 [M+H]+, found 522.2101. 
 
4.2.9.  3- (2´,3´ -O-Isopropylidene-5´-am ino-5´-
deoxyadenosine)-4-[(4-
m ethylbenzyl )am ino]cyclobut-3-ene-1,2-dione (20) 
To a solution of 3 (0.10 g, 0.33 mmol) in EtOH (3 mL) was 
added DIPEA (59 µL, 0.33 mmol) and 12 (0.080 mg, 0.33 
mmol). The reaction mixture was stirred at rt for 5 h and 
evaporated in vacuo. Purification of the crude product by column 
chromatography on silica gel (CHCl3/MeOH 10:1→ 4:1) gave 
compound 20 as a white solid (140 mg, 0.28 mmol, 85%). Rf = 
0.29 (CHCl3/MeOH, 10:1). 1H NMR (300 MHz, DMSO-d6) δppm 
8.31 (s, 1H), 8.17 (s, 1H), 7.64 (br s, 1H), 7.37 (br s, 3H), 7.25–
7.08 (m, 4H), 6.19 (s, 1H), 5.49–5.35 (m, 1H), 5.01 (dd, J = 6.2, 
3.4 Hz, 1H), 4.74–4.50 (m, 2H), 4.32–4.17 (m, 1H), 3.90 (br s, 
1H), 3.80–3.63 (m, 1H), 2.27 (s, 3H), 1.54 (s, 3H), 1.32 (s, 3H); 
13C NMR (75.4 MHz, DMSO-d6) δppm 182.7, 182.5, 167.5, 156.2, 
152.9, 148.8, 139.9, 136.6, 135.8, 129.2, 127.5, 119.2, 113.7, 
88.7, 85.2, 83.1, 81.2, 46.6, 45.2, 27.1, 25.3, 20.7; HRMS-ESI 
m/z calcd C25H28N7O5 506.2146 [M+H]+, found 506.2152. 
 
4.2.10.  3- (5´-Am ino-5´-deoxyadenosine) -4-[ (4-
f luorobenzyl )amino]cyclobut-3-ene-1,2-dione (24) 
A suspension of 16 (0.281 g, 0.55 mmol) in TFA/water (4:1, 10 
mL) was stirred at rt for 6 h. The solvent was evaporated in 
vacuo, and the residue was co-evaporated with toluene to remove 
any residual TFA and H2O. The remaining residue was purified 
by column chromatography on silica gel (CHCl3/MeOH 4:1) to 
give compound 24 as a light green solid (194 mg, 0.41 mmol, 
75% yield). Rf = 0.57 (CHCl3/MeOH, 10:1). 1H NMR (400 MHz, 
DMSO-d6) δppm 8.33 (s, 1H), 8.15 (s, 1H), 8.10 (br s, 1H), 7.80 
(br s, 1H), 7.41–7.31 (m, 2H), 7.29 (s, 2H), 7.21-7.10 (m, 2H), 
5.91 (d, J = 5.9 Hz, 1H), 5.57 (d, J = 6.1 Hz, 1H), 5.38 (d, J = 4.9 
Hz, 1H), 4.73-4.59 (m, , 3H), 4.20-4.12 (m, 1H), 4.06–3.97 (m, 
1H), 3.94 (br s, 1H), 3.85–3.72 (m, 1H); 13C NMR (101 MHz, 
DMSO-d6) δppm 182.6, 182.5, 168.0, 167.5, 161.5 (d, J = 243.0 
Hz), 158.0 (q, J = 30.9 Hz) 156.1, 152.7, 149.4, 139.8, 135.2, 
129.8 (d, J = 8.2 Hz), 119.2, 117.3 (q, J = 300.0 Hz), 115.4 (d, J 
= 21.4 Hz) 87.4, 83.6, 72.8, 70.8, 46.0, 45.6; HRMS-ESI m/z 
calcd C21H21FN7O5 470.1588 [M+H]+, found 470.1589. TFA 
 
4.2.11.  3- (5´-Amm onium-5´-deoxyadenosine) -4-
[ (3-nit rophenyl)am ino]cyclobut -3-ene-1,2-d ione 
t rif luoroace tate  (25) 
A suspension of 17 (88 mg, 0.16 mmol) in TFA/water (4:1, 3 
mL) was stirred at rt for 5 h. The solvent was evaporated in 
vacuo, and the residue was co-evaporated with toluene to remove 
any residual TFA and H2O. The remaining residue was purified 
by column chromatography on silica gel (CHCl3/MeOH 4:1) to 
give compound 25 as a yellow solid (63 mg, 0.13 mmol, 66% 
yield). Rf = 0.48 (CHCl3/MeOH, 4:1). 1H NMR (300 MHz, 
  
DMSO-d6) δppm 10.44 (br zs, 1H), 8.43 (br s, 1H), 8.35 (br s, 1H), 
8.22 (br s, 1H), 8.13 (s, 1H), 7.86–7.72 (m, 2H), 7.59 (t, J = 8.1 
Hz, 1H), 7.24 (br s, 2H), 5.94 (d, J = 5.6 Hz, 1H), 5.56 (d, J = 5.9 
Hz, 1H), 5.38 (d, J = 5.1 Hz, 1H), 4.71 (q, J = 5.5 Hz, 1H), 4.32–
4.21 (m, 1H), 4.14–3.99 (m, 2H), 3.97–3.83 (m, 1H); 13C NMR 
(75.4 MHz, DMSO-d6) δppm 184.4, 180.4, 169.7, 163.0, 157.9 (q, 
J = 30.9 Hz), 156.1, 152.7, 149.4, 148.6, 140.6, 139.9, 130.7, 
123.9, 119.2, 117.3 (q, J = 300.2 Hz), 116.6, 112.3, 87.6, 83.3, 
72.8, 70.8, 45.9; HRMS-ESI m/z calcd C20H19N8O7 483.1377 
[M+H]+, found 483.1378. 
 
4.2.12.  3- (5´-Am ino-5´-deoxyadenosine) -4-[ (4-
m ethoxybenzyl)am ino]cyclobut -3-ene-1,2-d ione 
(26) 
A suspension of 18 (0.10 g, 0.20 mmol) in TFA/water (4:1, 3 
mL) was stirred at rt for 5 h. The solvent was evaporated in 
vacuo, and the residue was co-evaporated with toluene to remove 
any residual TFA and H2O. The remaining residue was purified 
by column chromatography on silica gel (CHCl3/MeOH 4:1) to 
give compound 26 as a white solid (0.080 g, 0.17 mmol, 85% 
yield). Rf = 0.38 (CHCl3/MeOH, 4:1). 1H NMR (300 MHz, 
DMSO-d6) δppm 8.31 (s, 1H), 8.15 (s, 1H), 7.86 (br s, 1H), 7.57 
(br s, 1H), 7.27 (s, 2H), 7.22 (d, J = 8.3 Hz, 2H), 6.89 (d, J = 8.3 
Hz, 2H), 5.91 (d, J = 5.9 Hz, 1H), 5.52 (d, J = 5.9 Hz, 1H), 5.33 
(d, J = 4.2 Hz, 1H), 4.73–4.64 (m, 1H), 4.61 (d, J = 5.9 Hz, 2H), 
4.19–4.12 (m, 1H), 4.04–3.97 (m, 1H), 3.98–3.88 (m, 1H), 3.83–
3.74 (m, 1H), 3.72 (s, 3H); 13C NMR (75.4 MHz, DMSO-d6) δppm 
182.6, 182.4, 167.9, 167.4, 158.6, 156.1, 152.7, 149.4, 139.8, 
130.8, 128.9, 119.2, 114.0, 87.4, 83.6, 72.8, 70.8, 55.1, 46.2, 
45.5; HRMS-ESI m/z calcd C22H24N7O6 482.1788 [M+H]+, found 
482.1785. 
 
4.2.13.  3- (5´-Am ino-5´-deoxyadenosine) -4-[ (4-
m ethylbenzyl )am ino]cyclobut-3-ene-1,2-dione (28)  
A suspension of 20 (0.10 g, 0.20 mmol) in TFA/water (4:1, 3 mL) 
was stirred at rt for 5 h. The solvent was evaporated in vacuo, and 
the residue was co-evaporated with toluene to remove any 
residual TFA and H2O. The remaining residue was purified by 
column chromatography (CHCl3/MeOH 4:1, KP-NH column) to 
give compound 28 as solid (80 mg, 0.17 mmol, 85% yield). Rf = 
0.18 (CH2Cl2/MeOH, 4:1, NH2 TLC). 1H NMR (300 MHz, 
DMSO-d6) δppm 8.32 (s, 1H), 8.16 (s, 1H), 7.74 (br s, 1H), 7.45 
(br s, 1H), 7.33 (s, 2H), 7.16 (s, 4H), 5.92 (d, J = 5.9 Hz, 1H), 
5.57 (br s, 1H), 5.39 (br s, 1H), 4.75–4.54 (m, 3H), 4.22–4.10 (m, 
1H), 4.08–3.90 (m, 2H), 3.88–3.69 (m, 1H), 2.26 (s, 3H); 13C 
NMR (75.4 MHz, DMSO-d6) δppm 182.7, 182.6, 167.8, 167.5, 
156.1, 152.8, 149.4, 139.9, 136.6, 135.8, 129.2, 127.5, 119.3, 
87.5, 83.7, 72.8, 70.9, 46.6, 45.6, 20.7; HRMS-ESI m/z calcd 
C22H24N7O5 466.1839 [M+H]+, found 466.1840. 
 
4.2.14.  (9H -Fluoren-9-yl )m ethyl  [(S)-1-
[ [[(3aS,4S,6S,6aS) -6-(6-am ino-9H-purin-9-yl) -2,2-
d im ethylt et ra-hydrofuro[3,4-d] [1,3]dioxol-4-
y l]m ethyl ]amino]-3-(t er t-butoxy)-1-oxopropan-2-
y l] carbam ate (29) 
To a solution of 3 (0.10 g, 0.33 mmol) in anhydrous MeOH (10 
mL) was added Fmoc-L-Ser(tBu)-OSu (160 mg, 0.33 mmol). The 
reaction mixture was stirred at rt for 2.5 h under argon 
atmosphere. The solvents were removed in vacuo, and the residue 
was purified by column chromatography on silica gel 
(EtOAc/EtOH/n-heptane 3:1:4) to give compound 29 as a white 
solid (154 mg, 0.23 mmol, 70% yield). Rf = 0.65 (CHCl3/MeOH, 
10:1). 1H NMR (300 MHz, CDCl3) δppm 8.49 (s, 1H), 8.11 (s, 
1H), 7.82 (s, 1H), 7.72 (d, J = 7.6 Hz, 2H), 7.53 (t, J = 6.7 Hz, 
2H), 7.36 (t, J = 7.6 Hz, 2H), 7.30–7.21 (m, 2H), 5.93–5.86 (m, 
3H), 5.79 (d, J = 7.3 Hz, 1H), 5.35 (dd, J = 6.2, 4.1 Hz, 1H), 4.89 
(dd, J = 6.2, 2.5 Hz, 1H), 4.44 (s, 1H), 4.37 (d, J = 7.0 Hz, 2H), 
4.15 (t, J = 7.1 Hz, 1H), 3.92 (s, 1H), 3.74 (dd, J = 8.9, 3.9 Hz, 
1H), 3.52 (d, J = 7.5 Hz, 1H), 3.48 (s, 2H), 1.61 (s, 3H), 1.35 (s, 
3H), 1.10 (s, 9H); 13C NMR (75.4 MHz, CDCl3) δppm 171.2, 
156.0, 153.5, 149.2, 144.1, 143.9, 141.4, 140.3, 127.8, 127.8, 
127.2, 127.1, 125.2, 121.0, 120.1, 114.8, 92.0, 84.2, 83.2, 81.9, 
74.0, 67.3, 62.3, 55.5, 47.3, 41.6, 27.7, 27.5, 25.6.; HRMS-ESI 
m/z calcd C35H42N7O7 672.3146 [M+H]+, found 672.3146. 
 
4.2.15.  t er t-Butyl  (S)-3- [[[ (9H-fluoren-9-
y l)m ethoxy]carbonyl ]am ino] -4-[ [[(3aS,4S,6S,6aS)-
6- (6-am ino-9H -pur in-9-yl )-2, 2-
d im ethylt et rahydrofuro[3,4-d][1,3]di oxol-4-
y l]m ethyl ]amino]-4-oxobutanoate (30) 
To a solution of 3 (84 mg, 0.27 mmol) in anhydrous MeOH (10 
mL) was added Fmoc-L-Asp(OtBu)-OSu (140 mg, 0.27 mmol). 
The reaction mixture was stirred at rt for 2 h. The solvents were 
removed in reduced pressure and the residue was purified by 
column chromatography on silica gel (CHCl3/MeOH 10:1) to 
give compound 30 as a white solid (160 mg, 0.22 mmol, 75% 
yield). The product was used in the next step without further 
purification. Rf = 0.50 (CHCl3/MeOH, 10:1). 1H NMR (300 
MHz, CDCl3) δppm 8.56 (s, 1H), 8.43 (br s, 1H), 7.81 (s, 1H), 7.72 
(d, J = 7.6 Hz, 2H), 7.54 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.7 Hz, 
2H), 7.31–7.19 (m, 2H), 6.11 (br s, 2H), 5.98 (d, J = 8.7 Hz, 1H), 
5.83 (d, J = 4.5 Hz, 1H), 5.35 (t, J = 5.4 Hz, 1H), 4.89 (dd, J = 
6.4, 2.3 Hz, 1H), 4.63 (br s, 1H), 4.45 (s, 1H), 4.38 (d, J = 7.3 
Hz, 2H), 4.17 (t, J = 7.1 Hz, 1H), 4.03 (br s, 1H), 3.39 (d, J = 
14.7 Hz, 1H), 2.90–2.73 (m, 2H), 2.10 (br s, 1H), 1.60 (s, 3H), 
1.40 (s, 9H), 1.35 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δppm 
171.2, 170.3, 156.1, 156.0, 153.6, 149.1, 143.9, 143.8, 141.4, 
141.4, 140.3, 127.8, 127.2, 125.2, 120.9, 120.1, 114.7, 92.3, 83.8, 
82.8, 81.8, 81.7, 67.3, 51.9, 47.3, 41.5, 38.3, 28.2, 27.6, 25.5; 
HRMS-ESI m/z calcd C36H42N7O8 700.3095 [M+H]+, found 
700.3093. 
 
4.2.16.  (9H -Fluoren-9-yl )m ethyl  [(S)-1-
[ [[(2S,3S,4S, 5S) -5-(6-am ino-9H-purin-9-yl) -3,4-
d ihydroxytet ra-hydrofuran-2-yl ]m ethy l]am ino] -3-
hydroxy-1-oxopropan-2-yl] carbam ate (31) 
A solution of 29 (94 mg, 0.14 mmol) in TFA/H2O/CH2Cl2 (4:1:1, 
5 mL) was stirred at rt for 24 h. The solvent was evaporated in 
vacuo, and the residue was co-evaporated with toluene to remove 
residual TFA and H2O. The crude product was purified by 
column chromatography on silica gel (CH2Cl2/MeOH 0→15%) 
to give 31 as a white solid (56 mg, 0.10 mmol, 70% yield). Rf = 
0.21 (CHCl3/ MeOH, 10:1). 1H NMR (400 MHz, DMSO-d6) δppm 
8.44 (t, J = 5.9 Hz, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.25 (d, J = 
3.1 Hz, 1H), 7.88 (d, J = 7.5 Hz, 2H), 7.73 (t, J = 7.4 Hz, 2H), 
7.50–7.26 (m, 6H), 5.84 (d, J = 6.6 Hz, 1H), 5.33 (br d, J = 55.9 
Hz, 1H), 4.89 (br s, 1H), 4.67 (t, J = 5.8 Hz, 1H), 4.38–3.97 (m, 
6H), 3.69–3.48 (m, 4H), 3.42–3.31 (m, 1H); 13C NMR (101 
MHz, DMSO-d6) δppm 170.5, 156.0, 151.1, 149.0, 143.9, 143.8, 
140.9, 140.7, 127.6, 127.1, 125.3, 120.1, 119.4, 87.8, 83.8, 72.8, 
71.1, 65.8, 61.7, 57.3, 46.6, 41.1; HRMS-ESI m/z calcd for 
C28H30N7O7 576.2207 [M+H]+, found 576.2205. 
 
4.2.17.  (S)-3-[[ [(9H-Fluoren-9-
y l)m ethoxy]carbonyl ]am ino] -4-[ [[(2S,3S,4S, 5S) -5-
(6-am ino-9H-purin-9-yl) -3,4-
  
dihydroxytet rahydrofuran-2-yl]m ethyl ]am ino]-4-
oxobutanoic acid (33) 
A mixture of 30 (120 mg, 0.17 mmol) in TFA/H2O/CH2Cl2 
(5:1:4, 5 mL) was stirred at rt for 5 h. The solvent was removed 
in vacuo and the resulting residue was co-evaporated with 
toluene to remove any residual TFA and H2O. The crude product 
was purified by column chromatography on silica gel 
(MeOH/CHCl3 4:1) to give compound 33 as a white solid (110 
mg, 0.19 mmol, 90% yield). The product was used in the next 
step without further purification. Rf = 0.63 (MeOH/CHCl3, 4:1). 
1H NMR (300 MHz, DMSO-d6) δppm 12.27 (br s, 1H), 8.38 (app t, 
1Hz), 8.32 (s, 1H), 8.25 (s, 1H), 7.88 (d, J = 7.5 Hz, 2H), 7.70 (d, 
J = 7.4 Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.36–7.25 (m, 4H), 5.83 
(d, J = 6.5 Hz, 1H), 5.38 (br s, 1H), 5.21 (br s, 1H), 4.73–4.65 
(m, 1H), 4.46–4.37 (m, 1H), 4.30–4.15 (m, 4H), 4.04–3.97 (m, 
2H), 3.58–3.26 (m, 2H), 2.67 (dd, J = 16.4, 5.1 Hz, 1H), 2.56 (d, 
J = 8.9 Hz, 1H).; 13C NMR (75.4 MHz, DMSO-d6) δppm 171.6, 
171.1, 155.8, 154.1, 150.0, 148.8, 143.8, 143.7, 141.2, 140.6, 
127.6, 127.0, 125.3, 120.0, 119.3, 87.9, 83.7, 72.9, 71.1, 65.8, 
51.5, 46.6, 41.2, 36.4; HRMS-ESI m/z calcd for C29H30N7O8 
604.2156 [M+H]+, found 604.2164. 
 
4.2.18.  (S)-2-Am ino-N-[[ (2S,3S,4S,5S)-5- (6-am ino-
9H-purin-9-yl) -3 ,4-dihydroxytet rahydrofuran-2-
y l] -m ethy l]-3-hydroxypropanam ide (34) 
A mixture of 31 (0.037 g, 0.064 mmol) and DEA (7.5 µL, 
0.07 mmol) in DMF (0.50 mL) was stirred at rt for 5 h. The 
solvent was removed in vacuo to give a residual syrup that was 
purified by column chromatography (CHCl3/MeOH 0→15%, 
KP-NH column) to give compound 34 as white crystals (6.0 mg, 
0.017 mmol, 27 % yield). 1H NMR (400 MHz, CD3OD) δppm 8.28 
(s, 1H), 8.25 (s, 1H), 5.94 (d, J = 5.9 Hz, 1H), 4.80 (t, J = 5.7 Hz, 
1H), 4.23 (dd, J = 5.5, 3.7 Hz, 1H), 4.20–4.15 (m, 1H), 3.79 (dd, 
J = 14.2, 5.2 Hz, 1H), 3.74–3.63 (m, 2H), 3.50 (dd, J = 14.2, 4.2 
Hz, 1H), 3.45 (t, J = 5.6 Hz, 1H); 13C NMR (101 MHz, CD3OD) 
δppm 175.9, 157.5, 153.9, 150.5, 142.0, 120.9, 90.6, 85.1, 74.7, 
72.7, 65.5, 58.0, 42.2; HRMS-ESI m/z calcd for C13H20N7O5 
354.1526 [M+H]+, found 354.1526. 
 
4.3. Biochemical assays 
The expression construct for human MDO1 (residues 58-325) 
with an N-terminal 6×His tag and a thioredoxin fusion tag 
followed by a TEV cleavage site (pNH-TrxT) was a generous gift 
from the Structural Genomics Consortium, Oxford. DNA for 
MDO2 was a kind gift from Dr. Ahola (University of Helsinki, 
Finland). MDO2 (residues 7-243) was cloned to pNIC-Bsa4 
vector also containing a TEV cleavage site. MDO1 and MDO2 
were expressed by transforming the plasmids into E. coli 
Rosetta2 (DE3) cells. The purification protocol was similar for 
both enzymes. Glycerol stock was used to inoculate small 5-mL 
pre cultures grown overnight in Luria broth (LB) media which 
were then used to inoculate two large 1-L cultures containing 
Terrific broth (TB) auto induction media with trace elements 
(Formedium, UK). The media was additionally supplemented 
with 8 g/L glycerol. The cultures were allowed to grow up to 
OD600 of 1.5 at 37 °C with shaking after which the temperature 
was reduced to 18 °C and the cultures were allowed to grow 
overnight (14-16 h). The cells were then collected by 
centrifugation (5500×g, 25 min, 4 °C), resuspended in lysis 
buffer (50 mM HEPES, pH 7.5, 500 mM NaCl, 10% glycerol, 10 
mM imidazole, and 0.5 mM TCEP; 1.5 mL/g of cells) and stored 
at -20 °C. 
The cell suspension was thawed, 10 µg/mL DNAase, 0.1 mM 
Pefabloc, and 0.25 mg lysozyme was added followed by 
incubation on ice for 5 min. The cells were disrupted by 
sonication and the lysate was cleared by centrifugation (35000×g, 
30 min, 4 °C). The supernatant was filtered using a 0.45-µM 
filter syringe before it was loaded to two 1-mL HisTrap HP 
columns (GE Healthcare, UK), which were pre-charged with Ni2+ 
and pre-equilibrated with binding buffer (20 mM HEPES pH 7.5, 
500 mM NaCl, 10% glycerol, 10 mM imidazole, and 0.5 mM 
TCEP). The bound protein was washed with 5 column volumes 
(10 mL) of buffer supplemented with 25 mM imidazole and 
eluted with buffer containing 350 mM imidazole. The eluted 
protein fraction was concentrated and diluted in size exclusion 
buffer (20 mM HEPES, pH 7.5, 250 mM NaCl, 5% glycerol, and 
1 mM TCEP) to a final volume of 10 mL to bring the imidazole 
concentration down to 50 mM. TEV protease was added (1:30 
molar ratio) and the sample was incubated overnight at 4 °C. The 
cleaved protein was run again through a 1-mL HisTrap HP 
column (GE Healthcare, UK). The flow-through was collected 
and concentrated to perform size exclusion chromatography 
using Superdex S-75 column (GE Healthcare, UK). The collected 
fractions were pooled, concentrated and divided into small 
aliquots which were flash frozen in liquid nitrogen and stored at -
80 °C. Protein purity was analyzed with an SDS-PAGE 
(Supplementary Material S3). 
Compounds were tested as potential MDO1 inhibitors using a 
biochemical assay. A mono-biotin-ADP-ribosylated SRPK2 was 
used as a substrate for the hydrolysis as it can be robustly ADP-
ribosylated by ARTD10.29 A mixture of 2 µM substrate, 2 µM 
MDO1 and 0.8-1 mM compound was incubated in 25 mM 
HEPES pH 7.5, 100 mM NaCl for 16 hours. The reactions were 
stopped by adding 2× Laemmli buffer (Bio-Rad, USA) and 
incubating at 95 °C for 5 min. The samples were analyzed by 
SDS-PAGE and transferred onto a nitrocellulose membrane 
(Whatman, UK), which was blocked using 1% casein in 1× TBS 
buffer (Bio-Rad, USA). Finally, the samples were visualized with 
1:15000 streptavidin conjugated horseradish peroxidase 
(PerkinElmer, USA) using a chemiluminescent substrate 
(WesternBrightTM ECL, Advansta Corporation, USA). 
Dose-response measurements were performed using the 
previously reported Alphascreen-based activity assay for mono-
ADP-ribosyl hydrolyzing macrodomains.26 Compounds were 
measured in quadruplicates from 6.6 mM to 0.66 µM using half-
logarithmic dilutions. After transfer of compounds to the assay 
plate, MDO1 and MDO2 (final concentration 800 nM for both) 
were added to the plate followed by the addition of a mono-ADP-
ribosylated SRPK2 (final concentration 50 nM). The plate was 
incubated for 1 h 20 min at room temperature, followed by the 
addition of the acceptor and donor bead mixture (final 
concentration 5 µg/ml) and an incubation of 3 h at room 
temperature in dark. The luminescence was read with a Tecan 
Infinite M1000 Pro plate reader using the AlphaScreen detection 
module with 600 ms excitation and 300 ms integration time. 
 
4.4. Molecular modeling 
Preliminary dockings by us and others (see Supplementary 
Material S4) has shown that the MDO1 structure in its apo form 
is not able to accommodate ligands. We thus relied on a three-
dimensional structure where the binding site had been made to 
mimic the close homolog MDO2 bound to ADP-ribose. For this 
purpose, the human MDO1 protein was remodeled using the 
online webserver SWISS-MODEL.30 The best model was built 
based on human MOD2 structure (PDB file: 4IQY) with 56.33% 
sequence identity. Before docking, the modeled human MDO1 
protein structure (PDB code: 2X47) was handled with protein 
  
preparation wizard (Schrödinger Ltd). The protein was assigned 
atom type, side chain protonation states, and hydrogen network 
using PROPKA at pH 7.0. The OPLS3 force field was applied to 
minimize the protein. Glide receptor grids were generated by 
defining a 10 Å box localized at the centroid of ADP-ribose 
defined using the superimposed ADP-ribose-MDO2 protein 
complex. H-bond constraint to Asp160 was applied during grids 
generation, which will guarantee adenine stacked by Phe306 and 
Val183. 
All ligands listed in table 1 and 2 were drawn in 2D Sketcher, 
then converted into 3D. The possible ionization states of ligand 
were generated at pH 7.0+⁄-2.0 by LigPrep Suite.  
The molecular docking experiments were carried out with 
Maestro suite Glide and the Glide XP protocol.31 Default 
parameters were used. Van der Waals scale factor was 1.0, and 
partial charge cutoff was 0.25. For each ligand, the maximum 10 
docking poses were output. The one with lowest energy was 
suggested as most likely binding pose. 
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